Literature DB >> 14714587

Ultrasound assessment of the polycystic ovary: international consensus definitions.

Adam H Balen1, Joop S E Laven, Seang-Lin Tan, Didier Dewailly.   

Abstract

The polycystic ovary syndrome (PCOS) is a heterogeneous condition, the pathophysiology of which appears to be both multifactorial and polygenic. The definition of the syndrome has been much debated. Key features include menstrual cycle disturbance, hyperandrogenism and obesity. There are many extra-ovarian aspects to the pathophysiology of PCOS, yet ovarian dysfunction is central. At a recent joint ASRM/ESHRE consensus meeting, a refined definition of the PCOS was agreed, encompassing a description of the morphology of the polycystic ovary (PCO). According to the available literature, the criteria fulfilling sufficient specificity and sensitivity to define the PCO should have at least one of the following: either 12 or more follicles measuring 2-9 mm in diameter, or increased ovarian volume (> 10 cm3). If there is a follicle > 10 mm in diameter, the scan should be repeated at a time of ovarian quiescence in order to calculate volume and area. The presence of a single PCO is sufficient to provide the diagnosis. The distribution of follicles and a description of the stroma are not required in the diagnosis. Increased stromal echogenicity and/or stromal volume are specific to PCO, but it has been shown that the measurement of ovarian volume (or area) is a good surrogate for quantification of the stroma in clinical practice. A woman having PCO in the absence of an ovulation disorder or hyperandrogenism ('asymptomatic PCO') should not be considered as having PCOS, until more is known about this situation. Three-dimensional and Doppler ultrasound studies may be useful research tools but are not required in the definition of PCO. This review outlines evidence for the current ultrasound definition of the polycystic ovary and technical specifications.

Entities:  

Mesh:

Year:  2003        PMID: 14714587     DOI: 10.1093/humupd/dmg044

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  140 in total

1.  The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome.

Authors:  Richard S Legro; Allen R Kunselman; Robert G Brzyski; Peter R Casson; Michael P Diamond; William D Schlaff; Gregory M Christman; Christos Coutifaris; Hugh S Taylor; Esther Eisenberg; Nanette Santoro; Heping Zhang
Journal:  Contemp Clin Trials       Date:  2012-01-13       Impact factor: 2.226

2.  Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome.

Authors:  M Rizzo; R A Longo; E Guastella; G B Rini; E Carmina
Journal:  J Endocrinol Invest       Date:  2010-10-15       Impact factor: 4.256

3.  Lipid profile in relation to anthropometric indices and insulin resistance in overweight women with polycystic ovary syndrome.

Authors:  Maryam Saghafi-Asl; Saeed Pirouzpanah; Mehranghiz Ebrahimi-Mameghani; Mohammad Asghari-Jafarabadi; Soudabeh Aliashrafi; Bita Sadein
Journal:  Health Promot Perspect       Date:  2013-12-31

Review 4.  The role of genes and environment in the etiology of PCOS.

Authors:  Evanthia Diamanti-Kandarakis; Helen Kandarakis; Richard S Legro
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

5.  Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria.

Authors:  Miro Šimun Alebić; Tomislav Bulum; Nataša Stojanović; Lea Duvnjak
Journal:  Endocrine       Date:  2014-02-13       Impact factor: 3.633

Review 6.  The role of TGF-β in polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Margrit Urbanek; Raymond J Rodgers; Richard S Legro
Journal:  Reprod Sci       Date:  2013-04-12       Impact factor: 3.060

7.  Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features.

Authors:  Melissa Pawelczak; Lisa Kenigsberg; Sarah Milla; Ying-Hua Liu; Bina Shah
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

8.  Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives.

Authors:  Richard S Legro; Rebecca L Roller; William C Dodson; Christina M Stetter; Allen R Kunselman; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

9.  Prostate specific antigen in women with menstrual disturbances and fibrocystic mastopathy.

Authors:  S Radowicki; M Kunicki
Journal:  J Endocrinol Invest       Date:  2009-07-14       Impact factor: 4.256

Review 10.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.